Bioporto A/s · OMXCOP:BIOPOR
Bioporto A/s — Investor Presentation (2008)
6 slides from Bioporto A/s's investor presentation, 2008
Slide 1: Company presentation
Company presentation
Slide 2: Welcome
Welcome Lar pot repe Welcome BioPorto develops and markets Selection of antibodies and antibody-based Basic Clinical R monoclonal products, including tests to diagnose antibodies human disease, research for the research dia benefit of individual patients and to promote efficiency in the health secto
Slide 3: Organization and Board of Directors
Alliance with World-wide launch of Establishment of BioPorto is listed on the Statens Serum Institut the MBL product line BioPorto facilities Copenhagen Stock Exchange 2001 2002 2003 2004 Organization Chief Executive Officer Chief Financial Officer Board of Directors Carsten Lønfeldt, former CFO, Co
Slide 4: BioPorto's Selection Strategy
Strategy Launch of the world's Launch of CE-marked Positive Written Opinion on BioPorto's first first NGAL ELISA Kit NGAL Rapid ELISA Kit NGAL patent application 2005 2006 2007 BioPorto’s Selection Strategy BioPorto will seek to achieve as large a share of the routine diagnostic Large market market
Slide 5: Products: NGAL, MBL and AntibodyShop products
Products NGAL – is a new diagnostic biomarker for acute kidney injury • About 10% of hospital patients are at risk of developing renal failure and about 5% actually develop this dangerous condition • NGAL begins to rise within an hour of acute kidney injury, whereas current diagnostic methods only d
Slide 6: World-wide sales
Sales World-wide sales Market coverage by distributor Distributor location Market coverage by BioPorto Diagnostics/Direct sales BioPorto Diagnostics’ Europe 41% sales are 99% export North America 48% Asia 8% Other 3% BioPorto A/S Phone (+45) 4529 0000 Grusbakken 8 Fax (+45) 4529 0001 70200/032008/e